Drug Development
Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.
FEATURED STORIES
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
A new study on COVID-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection.
A new variant, C.1.2. is causing public health experts worldwide to keep an eye out for its presence as it seems to be more infectious and even more resistant to vaccines than other variants.
Regeneron and Sanofi broke ground with the 2017 approval of the first biologic drug for atopic dermatitis, the most common form of eczema driven by allergic reactions.
Shares of Bone Therapeutics are down more than 34% on the Euronext stock exchange after the company announced its Phase III osteoarthritis study failed to meet primary and critical secondary endpoints.
At the six-month mark, 68% of participants reported at least one persistent symptom, which fell to 49% after one year.
Scientists from the U.K. conducted a massive study on the link between vaccinations and dropping platelet counts and found that the problem lies more on the virus itself than on the medications.
It was a busy week for clinical trial news. Here’s a look.
Approximately 14,000 American women are expected to be diagnosed with invasive cervical cancer in 2021, and more than 4,000 are expected to succumb to the disease.
As many children go back to school, new waves of COVID-19 cases continue to surge. More data keeps coming in on potential vaccine risks and how they measure up against the risk of the disease. Here’s a look.
The CDC is taking a proactive stance and establishing a center that will use forecasting and outbreak analytics to guide public health decision-making.